CR-4-Health
CrossReg-4-Health: A Multicentre Prospective Cohort Study of Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Interreg VI-A Slovenia-Austria Programme, co-funded by the European Union (ERDF)
observational
300
2 countries
3
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Spontaneous intracerebral haemorrhage (ICH) is a severe form of stroke with high mortality and frequent long-term disability. Current tools to predict how an individual patient will recover are limited. CrossReg-4-Health is a prospective, multicentre observational cohort study that will enrol 300 consecutive adults with acute spontaneous ICH at three hospitals in Slovenia and Austria. During hospitalisation, the study will collect clinical data, standardised neurological and pain assessments, routine laboratory results, CT, CT angiography and MRI findings, and two research blood samples for biomarkers of brain injury, inflammation, coagulation and pain. Participants will be followed up at 6 and 12 months for survival, functional outcome, neurological status, pain, health-related quality of life, rehabilitation use and readmissions. The main aim is to develop a multimodal prognostic model for functional outcome (modified Rankin Scale) 12 months after ICH.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 12, 2026
Actual (reported)October 20, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Unfavourable functional outcome at 12 months (modified Rankin Scale 4-6)
Proportion of participants with mRS 4-6 (unfavourable) versus 0-3. The mRS ranges from 0 (no symptoms) to 6 (death); higher scores indicate worse outcome. Used as the outcome of the multivariable prognostic model.
12 months after ICH onset
Functional outcome on the full ordinal modified Rankin Scale at 12 months
12 months after ICH onset
Functional outcome at 6 months (modified Rankin Scale)
6 months after ICH onset
Consecutive adults with acute spontaneous intracerebral haemorrhage admitted to one of three participating centres, managed according to routine clinical practice.
Consecutive adults with acute spontaneous (non-traumatic) intracerebral haemorrhage admitted to stroke units, neurology wards, neurosurgical units or intensive care units of three hospital centres in Slovenia and Austria.
LKH-Universitätsklinikum Graz, Medical University of Graz
Graz, 8036, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, 9020, Austria
University Medical Centre Maribor, Department of Neurology
Maribor, 2000, Slovenia
Serum samples for biobank.
Martin Rakuša, MD, PhD
University Medical Centre Maribor
First Submitted
October 12, 2026
First Posted
October 20, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 31, 2028
EstimatedREmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH.
All-cause mortality
30 days, 6 months and 12 months after ICH onset
Change in neurological deficit (NIHSS) during hospitalisation
Admission, approximately 48 hours, and hospital discharge (up to approximately 4 weeks)
Neurological deficit at follow-up (NIHSS)
6 and 12 months after ICH onset
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 20, 2026
Record last verified: 2026-10
No, due to legal restrictions.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: